SCHEMBL586189

SCHEMBL586189

Cc1c(CC(=O)O)sc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
HSD11B1 P28845 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
PARP1 P09874 1/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
CNR2 P34972 3/20 0.41
CNR1 P21554 2/20 0.41
MCL1 Q07820 1/20 0.41
CYP1A2 P05177 2/20 0.41
POLB P06746 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
PTPN1 P18031 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30693720 1.00 PRNP (0.49) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL12359739 0.86 PRNP (0.45) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL7984331 0.85 HSD11B1 (0.48) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL4775819 0.85 TAS1R3 (0.44) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL5739446 0.85 RXFP1 (0.44) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL13911292 0.83 TAS1R3 (0.43) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL10315719 0.83 PRNP (0.47) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL11199425 0.82 TAS1R3 (0.45) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL2324454 0.82 TAS1R3 (0.45) PRNPRXFP1HSD11B1TAS1R3TAS1R1
SCHEMBL13900908 0.82 TAS1R3 (0.43) PRNPRXFP1HSD11B1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208998-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS UNIVERSITAT DE BARCELONA (ES) 2024-06-27 US disclosed
EP-4326262-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (ES) 2024-02-28 EP disclosed
CN-117320715-A Compounds for the treatment of hyperproliferative diseases 瓦尔希伯伦私人肿瘤研究基金会 2023-12-29 CN disclosed
WO-2022223704-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) 2022-10-27 WO disclosed
EP-4079304-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (ES) 2022-10-26 EP disclosed
CN-104672220-A Activating agent for peroxisome proliferator activated receptor NIPPON CHEMIPHAR CO 2015-06-03 CN disclosed
US-8802119-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
US-20130338107-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-12-19 US disclosed
US-8541581-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-09-24 US disclosed
US-20120088738-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS ,INC (US) 2012-04-12 US disclosed
WO-1997049708-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1997-12-31 WO disclosed
US-5700796-A USEFUL FOR TREATING CONGESTIVE HEART FAILURE, DISEASE CONDITIONS WITH EXCESS RENAL WATER REABSORPTION AND CONDITIONS WITH INCREASED VASULAR RESISTANCE AND CORONARY VASOCONSTRICTION AMERICAN CYANAMID COMPANY (US) 1997-12-23 US disclosed
EP-0804438-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS American Cyanamid Company (US) 1997-11-05 EP disclosed
US-5624923-A UROGENITAL AND CARDIOVASCULAR DISORDERS AMERICAN CYANAMID COMPANY (US) 1997-04-29 US disclosed
US-5612334-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1997-03-18 US disclosed
US-5610156-A USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1997-03-11 US disclosed
WO-1996022293-A1 TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
US-5536718-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1996-07-16 US disclosed
US-5516774-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1996-05-14 US disclosed
EP-0636625-A2 Tricyclic diazepine vasopressin antagonists and oxytocin antagonists AMERICAN CYANAMID COMPANY (US) 1995-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088738-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, CES1 PRNP 2404/4885RXFP1 280/4885HSD11B1 195/4885
US-20130338107-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, FFAR3 PRNP 2251/4885RXFP1 268/4885HSD11B1 240/4885
US-20240208998-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS VHL, PCNA, HRAS PRNP 4281/4885RXFP1 4664/4885HSD11B1 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.